BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38104891)

  • 1. Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
    Wei S; Krause HB; Geynisman DM; Elliott A; Kutikov A; Uzzo RG; Pei J; Barata P; Carneiro B; Heath E; Ryan C; Farrell A; Nabhan C; Ali-Fehmi R; Naqash AR; Argani P; McKay RR
    Mod Pathol; 2024 Feb; 37(2):100404. PubMed ID: 38104891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
    Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
    Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and Characterization of a
    Ishiguro M; Fukushige T; Iwasaki H
    Anticancer Res; 2023 Aug; 43(8):3463-3470. PubMed ID: 37500159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA like NMRK2 mRNA functions as a key molecular scaffold to enhance mitochondrial respiration of NONO-TFE3 rearranged renal cell carcinoma in an NAD
    Chen Y; Lu Y; Yang L; Ma W; Dong Y; Zhou S; Liu N; Gan W; Li D
    J Exp Clin Cancer Res; 2023 Sep; 42(1):252. PubMed ID: 37770905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
    Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
    Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
    Xiong L; Chen X; Liu N; Wang Z; Miao B; Gan W; Li D; Guo H
    PLoS One; 2017; 12(9):e0185337. PubMed ID: 28949976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
    Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
    Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
    Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
    Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
    Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
    Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
    Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
    Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRCC-TFE3 regulates migration and invasion of translocation renal cell carcinomas via activation of Drp1-dependent mitochondrial fission.
    Wang B; Gan W; Han X; Li D
    Cell Biol Int; 2020 Aug; 44(8):1727-1733. PubMed ID: 32339358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas.
    He J; Zhou K; Zhu B; Zhang G; Li X; Guo H; Gan W; Zhou Z; Liu T
    Biomed Res Int; 2015; 2015():298679. PubMed ID: 26636097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).
    Argani P; Antonescu CR; Couturier J; Fournet JC; Sciot R; Debiec-Rychter M; Hutchinson B; Reuter VE; Boccon-Gibod L; Timmons C; Hafez N; Ladanyi M
    Am J Surg Pathol; 2002 Dec; 26(12):1553-66. PubMed ID: 12459622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
    Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
    Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.